TY - JOUR
T1 - IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas
AU - Falini, Brunangelo
AU - Agostinelli, Claudio
AU - Bigerna, Barbara
AU - Pucciarini, Alessandra
AU - Pacini, Roberta
AU - Tabarrini, Alessia
AU - Falcinelli, Flavio
AU - Piccioli, Milena
AU - Paulli, Marco
AU - Gambacorta, Marcello
AU - Ponzoni, Maurilio
AU - Tiacci, Enrico
AU - Ascani, Stefano
AU - Martelli, Maria Paola
AU - Favera, Riccardo Dalla
AU - Stein, Harald
AU - Pileri, Stefano A.
PY - 2012/11
Y1 - 2012/11
N2 - Aims: The aim of this study was to search for a molecule selectively expressed by marginal zone (MZ) lymphomas (MZLs), whose diagnosis is currently based on morphological criteria and negativity for markers detectable in other B-cell lymphomas. Methods and results: Two thousand one hundred and four peripheral lymphomas of various types were immunostained with a monoclonal antibody against immunoglobulin superfamily receptor translocation-associated 1 (IRTA1), which recognizes the equivalents of MZ in human lymphoid tissues other than spleen. IRTA1 expression was restricted to extranodal (93%) and nodal MZLs (73%) and to lymphomas with MZ differentiation. Extranodal MZL cells with the strongest IRTA1 expression were usually located adjacent to epithelia, mimicking the IRTA1 expression pattern of normal and acquired mucosa-associated lymphoid tissue (MALT). The cytological features, growth pattern and IRTA1 positivity in nodal MZLs suggest they may derive from IRTA1+ perifollicular B cells or monocytoid B cells detectable in reactive lymph nodes. Double immunostaining for IRTA1/bcl-6 tracked the colonization of B-cell follicles by MZL cells, and showed modulation of their phenotype (e.g. acquisition of bcl-6) during recirculation through germinal centres. MZL cells differentiating into plasma cells usually lost IRTA1. Conclusions: These results further expand our knowledge of the biology of MZLs, and highlight IRTA1 as the first positive marker for MZLs, enabling more accurate diagnosis of these neoplasms.
AB - Aims: The aim of this study was to search for a molecule selectively expressed by marginal zone (MZ) lymphomas (MZLs), whose diagnosis is currently based on morphological criteria and negativity for markers detectable in other B-cell lymphomas. Methods and results: Two thousand one hundred and four peripheral lymphomas of various types were immunostained with a monoclonal antibody against immunoglobulin superfamily receptor translocation-associated 1 (IRTA1), which recognizes the equivalents of MZ in human lymphoid tissues other than spleen. IRTA1 expression was restricted to extranodal (93%) and nodal MZLs (73%) and to lymphomas with MZ differentiation. Extranodal MZL cells with the strongest IRTA1 expression were usually located adjacent to epithelia, mimicking the IRTA1 expression pattern of normal and acquired mucosa-associated lymphoid tissue (MALT). The cytological features, growth pattern and IRTA1 positivity in nodal MZLs suggest they may derive from IRTA1+ perifollicular B cells or monocytoid B cells detectable in reactive lymph nodes. Double immunostaining for IRTA1/bcl-6 tracked the colonization of B-cell follicles by MZL cells, and showed modulation of their phenotype (e.g. acquisition of bcl-6) during recirculation through germinal centres. MZL cells differentiating into plasma cells usually lost IRTA1. Conclusions: These results further expand our knowledge of the biology of MZLs, and highlight IRTA1 as the first positive marker for MZLs, enabling more accurate diagnosis of these neoplasms.
KW - Immunohistochemistry
KW - IRTA1
KW - Marginal zone lymphomas
KW - Monoclonal antibodies
UR - http://www.scopus.com/inward/record.url?scp=84868136434&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868136434&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2559.2012.04289.x
DO - 10.1111/j.1365-2559.2012.04289.x
M3 - Article
C2 - 22716304
AN - SCOPUS:84868136434
VL - 61
SP - 930
EP - 941
JO - Histopathology
JF - Histopathology
SN - 0309-0167
IS - 5
ER -